Literature DB >> 27064689

Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.

S Vasu1, H Wu2, A Satoskar2, M Puto3, J Roddy3, W Blum1, R Klisovic1, L Andritsos1, C Hofmeister1, D M Benson1, Y Efebera1, S Jaglowski1, S Penza1, D Cohen2, S Devine1, S Cataland1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27064689     DOI： 10.1038/bmt.2016.87

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  18 in total

1.  Eculizumab in atypical hemolytic-uremic syndrome.

Authors:  Christophe M Legendre; Christoph Licht; Chantal Loirat
Journal:  N Engl J Med       Date:  2013-10-03       Impact factor: 91.245

Review 2.  Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Corey Cutler; Shelly Carter; Paul Martin; Roberta Adams; Mary Horowitz; James Ferrara; Robert Soiffer; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2005-08       Impact factor: 5.742

3.  Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.

Authors:  Corey Cutler; N Lynn Henry; Colm Magee; Shuli Li; Haesook T Kim; Edwin Alyea; Vincent Ho; Stephanie J Lee; Robert Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2005-07       Impact factor: 5.742

Review 4.  Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments.

Authors:  John Chapin; Tsiporah Shore; Peter Forsberg; Garrett Desman; Koen Van Besien; Jeffrey Laurence
Journal:  Clin Adv Hematol Oncol       Date:  2014-09

Review 5.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

6.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Authors:  Marina Noris; Miriam Galbusera; Sara Gastoldi; Paolo Macor; Federica Banterla; Elena Bresin; Claudio Tripodo; Serena Bettoni; Roberta Donadelli; Elisabetta Valoti; Francesco Tedesco; Alessandro Amore; Rosanna Coppo; Piero Ruggenenti; Eliana Gotti; Giuseppe Remuzzi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

7.  The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.

Authors:  Michael A Pulsipher; Bryan Langholz; Donna A Wall; Kirk R Schultz; Nancy Bunin; William L Carroll; Elizabeth Raetz; Sharon Gardner; Julie M Gastier-Foster; Denise Howrie; Rakesh K Goyal; James G Douglas; Michael Borowitz; Yvonne Barnes; David T Teachey; Candace Taylor; Stephan A Grupp
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

8.  Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.

Authors:  Spero R Cataland; V Michael Holers; Susan Geyer; Shangbin Yang; Haifeng M Wu
Journal:  Blood       Date:  2014-04-02       Impact factor: 22.113

9.  Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Tsuyoshi Fukuda; Alexander Vinks; Kana Mizuno; Benjamin L Laskin; Jens Goebel; Bradley P Dixon; Ashley Teusink; Fred G Pluthero; Lily Lu; Christoph Licht; Stella M Davies
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-25       Impact factor: 5.742

10.  Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Authors:  Temitope Folaranmi; Lorry Rubin; Stacey W Martin; Manisha Patel; Jessica R MacNeil
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-12       Impact factor: 17.586
View more
  19 in total

1.  Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  S Machida; M Onizuka; M Toyosaki; Y Aoyama; H Kawai; J Amaki; R Hara; A Ichiki; Y Ogawa; H Kawada; K Ando
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

Review 2.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

3.  Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD.

Authors:  Sarah A Wall; Qiuhong Zhao; Martha Yearsley; Luke Blower; Akwasi Agyeman; Parvathi Ranganathan; Shangbin Yang; Haiwa Wu; Matthew Bostic; Samantha Jaglowski; Jonathan E Brammer; Basem William; Hannah Choe; Alice S Mims; Sam Penza; Yvonne Efebera; Steven Devine; Spero Cataland; Stella M Davies; Sumithira Vasu
Journal:  Blood Adv       Date:  2018-10-23

4.  Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study.

Authors:  Li-Ping Yang; Peng Zhao; Ye-Jun Wu; Hai-Xia Fu; Yun He; Xiao-Dong Mo; Meng Lv; Feng-Rong Wang; Chen-Hua Yan; Yu-Hong Chen; Ying-Jun Chang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Bone Marrow Transplant       Date:  2022-01-25       Impact factor: 5.483

5.  Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.

Authors:  Christopher D Hamad; Zachary C Hoelscher; Amanda Tchakarov; Jaya Kala
Journal:  CEN Case Rep       Date:  2022-01-07

Review 6.  Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Authors:  E Gavriilaki; I Sakellari; A Anagnostopoulos; R A Brodsky
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

Review 7.  HUS and atypical HUS.

Authors:  T Sakari Jokiranta
Journal:  Blood       Date:  2017-04-17       Impact factor: 25.476

8.  Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature.

Authors:  Eric Wirtschafter; Christine VanBeek; Yuliya Linhares
Journal:  Exp Hematol Oncol       Date:  2018-06-22

Review 9.  Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation.

Authors:  Thomas Luft; Peter Dreger; Aleksandar Radujkovic
Journal:  Bone Marrow Transplant       Date:  2021-07-12       Impact factor: 5.483

10.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.